Peter A. Fasching
Goethe University Frankfurt(DE)Universität Hamburg(DE)Friedrich-Alexander-Universität Erlangen-Nürnberg(DE)Heidelberg University(DE)University Hospital Heidelberg(DE)Gentofte Hospital(DK)Universitätsklinikum Erlangen(DE)Klinik für Frauenheilkunde(DE)University Medical Center Hamburg-Eppendorf(DE)Comprehensive Cancer Center Erlangen(DE)NSABP Foundation(US)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, BRCA gene mutations in cancer, Ovarian cancer diagnosis and treatment
Most-Cited Works
- → Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis(2014)4,584 cited
- → Pembrolizumab for Early Triple-Negative Breast Cancer(2020)2,940 cited
- → Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes(2012)2,632 cited
- → Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer(2018)2,534 cited
- → Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy(2017)2,068 cited
- → Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes(2018)1,152 cited